1C3S

CRYSTAL STRUCTURE OF AN HDAC HOMOLOG COMPLEXED WITH SAHA

1C3S の概要

• エントリーDOI: 10.2210/pdb1c3s/pdb
• 関連するPDBエントリー: 1C3R 1C3S
• 分子名称: HDLP (HISTONE DEACETYLASE-LIKE PROTEIN), ZINC ION, OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE, ... (4 entities in total)
• 機能のキーワード: alpha/beta fold, hydroxamic acid, penta-coordinated zinc, charge-relay system, lyase
• 由来する生物種: Aquifex aeolicus
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 43031.37

構造登録者

Finnin, M.S.,Donigian, J.R.,Pavletich, N.P. (登録日: 1999-07-28, 公開日: 1999-09-15, 最終更新日: 2024-02-07)

主引用文献

Finnin, M.S.,Donigian, J.R.,Cohen, A.,Richon, V.M.,Rifkind, R.A.,Marks, P.A.,Breslow, R.,Pavletich, N.P.
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.
Nature, 401:188-193, 1999

PubMed Abstract: Histone deacetylases (HDACs) mediate changes in nucleosome conformation and are important in the regulation of gene expression. HDACs are involved in cell-cycle progression and differentiation, and their deregulation is associated with several cancers. HDAC inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), have anti-tumour effects, as they can inhibit cell growth, induce terminal differentiation and prevent the formation of tumours in mice models, and they are effective in the treatment of promyelocytic leukemia. Here we describe the structure of the histone deacetylase catalytic core, as revealed by the crystal structure of a homologue from the hyperthermophilic bacterium Aquifex aeolicus, that shares 35.2% identity with human HDAC1 over 375 residues, deacetylates histones in vitro and is inhibited by TSA and SAHA. The deacetylase, deacetylase-TSA and deacetylase-SAHA structures reveal an active site consisting of a tubular pocket, a zinc-binding site and two Asp-His charge-relay systems, and establish the mechanism of HDAC inhibition. The residues that make up the active site and contact the inhibitors are conserved across the HDAC family. These structures also suggest a mechanism for the deacetylation reaction and provide a framework for the further development of HDAC inhibitors as antitumour agents.

PubMed: 10490031
DOI: 10.1038/43710

実験手法

X-RAY DIFFRACTION (2.5 Å)